Profhilo
Profhilo for enlarged pores: what can a ten-person pilot study tell us?
A 2026 pilot reported less visible facial pores after two sessions, but its ten participants, lack of a control group and photographic assessments cannot prove how much change Profhilo caused.
Visible pores are not one simple problem
Pores are normal openings on the skin surface. They may look more noticeable because of oil, congestion, previous acne, reduced support around the opening, sun-related change or the way light falls across skin texture. A close-up photograph can also exaggerate them. Consultation should therefore establish what the person means by ‘large pores’ before discussing treatment.
Profhilo is an injectable hyaluronic-acid treatment intended to improve selected aspects of skin quality. It does not remove pores, stop normal oil production, treat active acne or replace assessment of a changing skin lesion. Even when surrounding skin appears smoother, pores remain part of normal anatomy and a completely poreless result is not realistic.
What did the 2026 pilot study involve?
The prospective observational study included ten healthy adults aged 32 to 52 with visible facial pores and early signs of skin ageing. Nine were women and one was a man. Each participant received two treatment sessions 30 days apart, using five standardised injection points on each side of the face, and no comparison or untreated group was included.
Researchers assessed participants at baseline and on days 30, 60, 120 and 180. They used standardised photographs, clinical assessment and rating scales rather than an instrumental pore-measurement system. The same experienced practitioner performed every procedure. This creates a consistent protocol, but it does not show how the treatment compares with skincare, another procedure, saline injections or no treatment.
What was reported?
The authors reported that pores and overall skin texture looked improved after treatment. Nine of the ten participants appeared to have their greatest pore refinement around day 120. By day 180, nine showed some regression from their best result, although their appearance was still judged favourable compared with baseline.
This pattern suggests a possible temporary change, but it cannot establish a standard maintenance interval. Participants knew they had been treated, there was no blinded control, and normal variation in hydration, lighting, skincare or camera conditions could contribute. The study was descriptive and not powered to provide a reliable estimate of how likely or how large a visible response might be.
Why association is not proof of cause
Without a control group, improvement after treatment is not the same as improvement caused by treatment. The study had only ten people from a narrow age range, relied substantially on photographs and clinical judgement, and did not objectively measure pore volume. Its authors appropriately described the findings as preliminary and called for larger randomised controlled trials.
The study proposed that hydration, dermal support and extracellular-matrix changes might help explain the result, but it did not directly measure these mechanisms. A 2026 systematic review of broader Profhilo research also noted that all nine included studies were single-centre, most were small and their outcome methods varied. Several review authors worked for the manufacturer, which should be considered when interpreting its conclusions.
Downtime and adverse effects
No adverse events were reported in the ten-person pilot, but a study this small cannot establish that complications do not occur. Expected short-term effects can include stinging, tenderness, redness, swelling, bruising, itching and small raised points at injection sites. The systematic review found that reported injection-site effects were generally mild and resolved within a few days.
Increasing pain, spreading redness or heat, discharge, fever, marked or persistent swelling, firm or enlarging lumps, unusual pale or mottled skin, eye pain or visual symptoms need prompt clinical assessment. Sterile technique, an authentic traceable product, written aftercare and access to a suitably qualified clinician remain important even when the proposed benefit is subtle.
Suitability and expectations must be individual
Consultation should examine the skin, clarify whether the concern is pores, congestion, scarring or another condition, and review skincare and previous procedures. Medical conditions, medicines, allergies, pregnancy or breastfeeding, active acne, infection or inflammation and planned events may affect suitability or timing. Sometimes appropriate skincare, acne treatment, another procedure or no intervention is more proportionate.
A balanced discussion should cover the limited evidence, likely subtle and temporary change, two-session treatment burden, downtime, total cost, alternatives and follow-up. GMC guidance requires honest information about risks and lower-risk options. This pilot supports further research into pore appearance; it does not justify promising a particular percentage improvement or booking maintenance solely because a calendar date has arrived.